Amgen cracks the undruggable code, earning the FDA's nod for first-ever KRAS inhibitor
Among the most famous “undruggable” targets in oncology is mutated KRAS — a cell surface protein tied to a range of aggressive cancer types. Looking to overcome the industry’s years of failures, Amgen finally appeared to crack the code and raced its lead compound through clinical trials.
Now, just three short years later, that drug is ready for showtime.
The FDA on Friday approved Amgen’s Lumakras (sotorasib), a novel KRAS inhibitor for pretreated non-small cell lung cancer patients with the KRAS-G12C mutation, the agency said.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 109,900+ biopharma pros reading Endpoints daily — and it's free.